Compare Ascendis Pharma A/S (ASND) vs Prudential PLC (PUK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Prudential PLC — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Prudential PLC trades at $28.23 (market cap $34.34B). The key difference: Prudential PLC is the larger of the two by market cap, and Prudential PLC pays a 1.89% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PUK | |
|---|---|---|
Market Cap | $17.74B | $34.34B |
Sector | Health | Financials |
52-Week High | $277.18 | $33.61 |
52-Week Low | $163.32 | $24.65 |
Enterprise Value | $18.11B | $35.78B |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Prudential Financial (PUK) trades at $28.13, up 1.33% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 9.16, net income margin of 14.52%, and recent earnings beats. Revenue grew to $16.21B in 2024, with net income reaching $2.29B. Analyst consensus is 50% buy, 37.5% hold, and 12.5% sell. Recent news highlights Q2 2026 earnings anticipation and strategic moves in India.
Outlook is positive with robust profitability and valuation appeal, but risks include Japan sales suspension and regulatory scrutiny. The stock offers growth potential from international expansion, supported by solid cash flow and equity performance. Investors should weigh near-term headwinds against long-term strategic positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
